Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.31 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21398891 | 0.78 | MAPT (0.32) | MAPTIP6K1IP6K3 | |
| SCHEMBL21399055 | 0.71 | ALDH1A1 (0.38) | MAPTPKMPOLBIRAK4 | |
| SCHEMBL24867055 | 0.69 | MAPT (0.32) | MAPTIRAK4 | |
| SCHEMBL21388724 | 0.67 | CHRNB2 (0.39) | — | |
| SCHEMBL21380948 | 0.66 | IP6K1 (0.31) | IP6K1IP6K3 | |
| SCHEMBL23339220 | 0.65 | NOS1 (0.40) | MAPT | |
| SCHEMBL21399022 | 0.65 | MAPT (0.34) | MAPTPOLB | |
| SCHEMBL21388796 | 0.57 | HPGD (0.47) | MAPTPKMPOLB | |
| SCHEMBL24866477 | 0.56 | KDM4E (0.42) | MAPTPKMPOLB | |
| SCHEMBL21380967 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | PTPN11 10/4885MAPT 4707/4885PKM 3290/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | PTPN11 10/4885MAPT 4707/4885PKM 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.